A Phase 1 Parallel Open-Label Study of the Safety and Tolerability Pharmacokinetics and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Brief description of study
The purpose of the study is to determine the safety of ASTX660 alone and in combination with ASTX727 in patients who have acute myeloid leukemia (AML) and they are unfit for intensive chemotherapy or they have relapsed or they are unresponsive to treatment.
Clinical Study Identifier: s19-01072
ClinicalTrials.gov Identifier: NCT04155580
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
